Rep. Chuck Edwards

Maddy summaryHR 6895, the Debt Solution and Accountability Act, requires the Treasury Secretary to submit detailed reports to Congress before increasing the debt limit. These reports must include current and projected debt levels, drivers of future debt, plans to reduce debt growth (short, medium, and long-term), and analyses of how debt limit actions affect government spending, debt service, and the dollar's global role. The bill also mandates a progress report within 180 days after any debt limit increase or suspension, and requires public posting of all reports on Treasury's website for six months. Additionally, it grants congressional committees specific access to Treasury financial data upon request, including cash flow details and debt transaction information. The bill focuses solely on transparency and reporting requirements, without altering debt policy or spending levels.

Maddy summaryThis bill establishes a digital system for TRICARE members to electronically file and track complaints about access to care at military medical facilities. It requires the Defense Department to create a system where beneficiaries can submit complaints online, view their status in real time, and have complaints automatically aggregated quarterly for review. The system mandates annual reports to Congress comparing complaint types (e.g., specialty vs. primary care, pediatric vs. non-pediatric, administrative hurdles) and detailing facility-level actions taken to address issues. The goal is to improve transparency and accountability in military healthcare access.

Essential Caregivers Act of 2025   This bill prohibits certain health care facilities from limiting the access of essential caregivers to residents of those facilities, including during designated emergency periods.   Specifically, the bill generally prohibits Medicare skilled nursing facilities, Medicaid nursing facilities, Medicaid intermediate care facilities, and associated inpatient rehabilitation facilities from restricting the access of essential caregivers to residents of the facilities, including during emergency periods in which visitation rights are otherwise restricted. During emergency periods, facilities may restrict access for an initial period of up to seven days and for one additional maximum seven-day period (if the additional period is approved by the state health department). Facilities may restrict access for a total of 7 days (or 14 days with the approval of the state health department) during an emergency period. Essential caregivers must agree to comply with any safety protocols set by the facility, which may be no more stringent for caregivers compared to those for staff. Caregivers who fail to comply with these requirements may be denied access, subject to an appeals process.

Maddy summaryHR 6718, the Professional Student Degree Act, amends the Higher Education Act to clarify the definition of a "professional degree" for federal education purposes. It replaces the previous definition with a new section listing specific degrees that meet the criteria, including Pharmacy (Pharm.D.), Law (J.D.), Medicine (M.D.), Dentistry (D.D.S.), Veterinary Medicine (D.V.M.), and others like Nursing (D.N.P.) and Business Administration (M.B.A.). This definition requires degrees to signify both completion of academic requirements for professional practice (often requiring licensure) and skills beyond a bachelor's level. The bill directly affects students pursuing these designated degrees by formally recognizing them under federal education law, without creating new programs or changing funding.

Miracle on Ice Congressional Gold Medal Act This act provides for the award of Congressional Gold Medals to the members of the 1980 U.S. Olympic men's ice hockey team in recognition of the team's achievement at the 1980 Winter Olympic Games.

Maddy summaryThe Safer Schools Act of 2025 establishes a 5-year federal pilot program providing grants to public schools for security risk assessments and physical security upgrades. Public schools that have experienced violent incidents involving multiple people are prioritized for both types of grants. Schools receiving assessment grants must first identify vulnerabilities, while improvement grants fund specific security measures like panic alarms linked to local police, with federal funds covering up to 50% of costs. The program allocates $600 million total ($100M-$300M annually), requiring schools to submit financial reports and post-implementation safety surveys, with annual congressional reports tracking outcomes.

Maddy summaryHR 1623 (the SCREEN Act) requires online platforms that profit from hosting pornographic content to implement age verification technology, preventing minors from accessing such material. Covered platforms must publicly disclose their verification process and securely handle age data collected through these systems. The law applies specifically to platforms where pornographic content is a regular business activity, not all websites. It mandates that only adults can access pornographic content on these platforms, without banning the content itself.

Maddy summaryHR 573, the "Studying NEPA’s Impact on Projects Act," requires the Council on Environmental Quality (CEQ) to annually publish detailed reports starting July 2025 on how the National Environmental Policy Act (NEPA) affects federal projects. The reports will track NEPA-related lawsuits (including outcomes and costs), the length and cost of environmental reviews (like impact statements), and timelines for completing key review steps over 5- to 10-year periods. Data must be broken down by project type (e.g., energy, transportation) and sector (e.g., renewable energy, pipelines) to show trends in compliance, delays, and expenses. This information will be made publicly available online and submitted to relevant congressional committees, providing transparency on NEPA’s practical implementation without changing the law itself.

Maddy summaryHR 6509, the SAFE Drugs Act of 2025, limits how often pharmacies and healthcare providers can create custom drug formulations that copy standard medications. It restricts compounding any drug essentially identical to a commercially available product to no more than 20 times per month for individual patients. The bill also requires pharmacies compounding such drugs for out-of-state patients more than 20 times monthly to report details to the FDA, while exempting hospital pharmacies. These changes aim to improve safety oversight of non-standard drug compounding by setting clear limits and reporting rules.

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.  Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.  The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)